Source: Unsplash/Louis Reed

News • Surprising similarities

These are the top 25 medical lab tests around the world

A recent study can help governments understand which diagnostic laboratory tests are most important when developing universal health coverage systems. Researchers from five countries found that diagnostic laboratory tests are used similarly around the world, even though the institutions they studied differed in terms of poverty levels, health systems and prevalence of disease.

The interpretation is that human biology is similar across the globe, which affects the type of tests needed

Susan Horton

“Even though poorer countries have many more infectious diseases, while richer ones suffer more from non-communicable diseases like stroke, diabetes and heart conditions, the patterns of tests were surprisingly similar across these countries,” said Susan Horton, a public health professor at the University of Waterloo and the study’s principal investigator. “The interpretation is that human biology is similar across the globe, which affects the type of tests needed.”

The researchers obtained data on the 25 most common tests at five teaching hospitals, ranging from lower-middle to high income, located around the world: Kenya, India, Nigeria, Malaysia and the U.S. Two were private hospitals, while three were public. They compared the volume of tests, as well as their prices, and found that the same tests were common everywhere. In terms of prices for different types of tests at each hospital, the researchers compared the most common biochemical test (blood glucose), the most common hematologic test (CBC), the most common microbiology test (urine culture), and histopathologic tests overall (surgicals). 

The study was published in the American Journal of Clinical Pathology.

These are the top 25 medical lab tests around the world

Image by Michal Jarmoluk from Pixabay

They found that even though the relative prices varied, the biochemical test price was lowest in each hospital, the hematology and microbiology test prices were about three times as high, and the histopathology test price about 15 times as high as the price of the biochemical test.

In terms of volume, four of the top five tests were the same across four of the hospitals, and the fifth hospital had three that were the same. Surprisingly, a test for diagnosing tuberculosis only appeared in the top 25 in one hospital, despite the prevalence of the disease in some countries. The researchers hypothesize that the tests are taking place outside the hospital system, such as TB-dedicated facilities. “As countries around the world attempt to implement universal health coverage, their health care systems will require better, affordable and effective laboratory tests to guide diagnosis and treatment,” said Horton. “One important implication is that the new Essential Diagnostics List issued by the World Health Organization (WHO) in 2018 is likely to be a powerful tool — and given that most of the tests on our top 25 list were also included on the WHO list, these findings have the potential to inform plans for universal health coverage.” 

Horton added that more data needs to be collected from a more representative set of health facilities in each country, especially as they develop their own essential diagnostics lists.


Source: University of Waterloo

23.05.2019

Read all latest stories

Related articles

Photo

News • Biomarker from blood test

Lung cancer: Liquid biopsy accurately predicts immunotherapy response

A simple blood test could be a better predictor of whether cancer immunotherapy will be successful for a patient with lung cancer than an invasive tumor biopsy procedure.

Photo

Article • To the core

Mass spec needs experienced operators

As mass spectrometry proves to be a more consistent and accurate tool in biochemical measures, with acknowledged advantages over immunoassays, its role in diagnostics has escalated. Headed by…

Photo

News • Acquisition

Oxford Gene Technology to be acquired by Sysmex Corporation

Oxford Gene Technology (OGT), The Molecular Genetics Company, today announced that it has signed an agreement to be acquired by Sysmex Corporation, a Japanese in vitro diagnostic company.

Related products

Sarstedt – Tempus600 Vita

Sample Logistics

Sarstedt – Tempus600 Vita

SARSTEDT AG & CO. KG
Shimadzu – LCMS-8060NX CL (IVD) / LCMS-8060 NX (RUO)

Mass Spectrometry

Shimadzu – LCMS-8060NX CL (IVD) / LCMS-8060 NX (RUO)

Shimadzu Europa GmbH
Alsachim - Dosimmune immunosupressant Alsachim – kit (CE-IVD or RUO)

Clinical Chemistry

Alsachim - Dosimmune immunosupressant Alsachim – kit (CE-IVD or RUO)

Alsachim, a Shimadzu Group Company
Alsachim – Dosimyco immunosupressant reagent kit (RUO)

Clinical Chemistry

Alsachim – Dosimyco immunosupressant reagent kit (RUO)

Alsachim, a Shimadzu Group Company
Alsachim – Dosinaco anticoagulant reagent kit (RUO)

Clinical Chemistry

Alsachim – Dosinaco anticoagulant reagent kit (RUO)

Alsachim, a Shimadzu Group Company
ASP Lab Automation – SortPro Sample sorter

Sample Processing

ASP Lab Automation – SortPro Sample sorter

ASP Lab Automation AG
Subscribe to Newsletter